Resources / events

Corporate Literature

BioDuro-Sundia Services & Capabilities Overview

BioDuro-Sundia understands the value our clients place on partnering with the right CRO/CDMO. We work as true partners throughout the discovery, development and manufacturing process, to provide a new and reliable source of efficiencies, ideas and innovation, while ensuring an exceptional customer experience

Fact Sheets

Scale-up Chemistry

BioDuro-Sundia develops robust and cost-effective chemistry processes from early discovery to kilogram quantity process chemistry. Learn more about our capabilities by downloading our fact sheet below. 


From early discovery to IND-enabling studies, BioDuro provides world-class quality data for in vitro ADME and in vivo PK studies. Learn more about our capabilities by downloading our fact sheet below. 

Ames Mutagenicity Test

Screen compounds early in the drug discovery process to identify compounds with mutagenic potential. Learn more about our capabilities by downloading our fact sheet below. 

Recombinant Protein Production

At BioDuro we offer recombinant protein expression in bacterial, insect, and mammalian systems. Learn more about our capabilities by downloading our fact sheet below. 


BioDuro-Sundia provides preclinical solutions for anti-cancer drug discovery in 2D and 3D cellular models and animal tumor models. Learn more about our capabilities by downloading our fact sheet below. 

hTME-3DX Screen and Verify™

BioDuro-Sundia offers the first drug screening platform to combine humanized 3D tumor models in vitro and follow-on in vivo PDX capability, matched to same primary patient sample.  Learn more about hTME-3DX Screen and Verify™ by downloading our fact sheet below. 

Human Tumor Biobank

Through the acquisition of Molecular Response, BioDuro-Sundia’s oncology platform comprises the world’s largest viable tumor collection of over 100,000 biospecimens. Learn more about our capabilities by downloading the fact sheet below.

Metabolic Disease

Our Pharmacology team provides comprehensive in vivo assays and animal models for studying efficacy and mechanism of action of drug candidates.

Immunology and Inflammatory Disease

BioDuro-Sundia Pharmacology provides in vitro assays and disease models for inflammatory and autoimmune diseases to help our clients evaluate the efficacy of their compounds.

Analytical Development

BioDuro-Sundia Analytical Development provides necessary data for the development process from discovery candidates to clinical trial materials. Learn more about our capabilities by downloading our fact sheet below. 

Drug Product Manufacturing

BioDuro-Sundia offers cGMP manufacturing services with quality, efficiency and timeliness of delivery in mind.  Learn more about our capabilities by downloading our fact sheet below. 

Amorphous Solid Dispersions

BioDuro-Sundia has extensive experience and a range of bioavailability enhancement solutions for poorly soluble compounds. Learn more about our capabilities by downloading our fact sheet below. 

Scientific Posters

LOCUS: Queryable Database of Cancer Genomics and Pharmacologic Response Enables Rapid Selection of Preclinical Tumor Models

LOCUS: Queryable Database of Cancer Genomics and Pharmacologic Response Enables Rapid Selection of Preclinical Tumor Models” was presented at AACR 2019 by Dr. Tommy Broudy.

Enteric Solid Dosage Formulation for Physiologically Active Proteins and Peptides

Poster on study aimed at developing an enteric solid dosage formulation, allowing oral administration of a physiologically active protein.

Effect of Additives on Preparation of Posaconazole Nano-Suspensions

The purpose of this study was to evaluate additives that can be used to prepare stable Posaconazole nano-suspensions as a precursor to oral dosage forms containing nanoparticles.

Effect of Nozzle Mechanism and Spray Dried Dispersion Parameters on Final Dissolution of Spray Dried Tablets

Scientific poster investigating the effect of change from a pressure nozzle to a two fluid nozzle on final quality attributes of a spray dried formulation of tablets and to determine the potential cause of quality attribute changes

Ex Vivo Three-dimensional Tumor Growth Assay: 3DX-TGA

Poster on the establishment, serial propagation and molecular characterization of 300+ ex vivo 3D (3DX) models spanning 16 tumor indications, as a practical alternative to PDX models. Presented by Brett Hall, Ph. D.,  at AACR 2017. 

hTME-3DX Screen and Verify™ is based on the proprietary primary tumor bank and 3D drug screening platform that was developed by Molecular Response, through a large body of academic and commercial research over the past decade, as well as, internal expertise in ex vivo cell cultures and human tumor sample preservation.

Novel Gastro-Retentive Formulation for Methyldopa Using Hot Melt Extrusion (HME) Technology

Poster on formulation of a novel gastro-retentive sustained release oral formulation for methyldopa to treat Type I diabetes, presented by Ruchit Trivedi, Ph. D.,  at AAPS 2016. 

Reducing Residual Crystallinity in Hot Melt Extrusion (HME) Formulations Optimization

Poster on improvement of existing hot melt extrusion formulations showing recrystallization due to moisture absorption, and high percentage impurities, presented at AAPS 2016.

Microevaporative Dispersion as a Predictor of Dissolution Performance of Amorphous Dosage Forms

Poster on microevaporative dispersion as an early predictor of dissolution performance of amorphous dosage forms.

Multiparticulate Drug Delivery System for Physiologically Active Proteins and Peptides

Poster on the development of a multiparticulate drug delivery system for physiologically active proteins that can be administered as an oral suspension, or through nasogastric tubes.


Rapid Development and Scale-up of Solubilized Dosage Forms

Hear from Ruchit Trivedi Ph.D., Associate Director of Formulation at BioDuro-Sundia on strategies for developing poorly soluble drugs. He discusses the advantages of amorphous materials and solubilization approaches using spray drying and hot melt extrusion.

Enabled Formulations Bridging Discovery and Development

Hear BioDuro-Sundia’s CSO of Global CMC Solutions, Blair West, Ph.D., present on challenges and opportunities in late discovery and early development formulation and how a multidisciplinary approach that integrates areas such as formulation development and DMPK can accelerate the development pathway.

Paving the Road to the Clinic: Translational Oncology & Immuno-oncology Tumor Models

Hear from Tommy Broudy, Executive Vice President, Translational Sciences & Strategy on clinically relevant models for anti-cancer drug discovery. He discusses in vitro and in vivo models, the importance of the tumor microenvironment, and preclinical immunoprofiling of patient populations.

Integrated Drug Development at BioDuro


Formulation & Drug Delivery Congress USA

March 18-19th, 2019
San Diego, CA

American Association of Cancer Research Annual Meeting

March 29th-April 3rd, 2019
Atlanta, GA
Booth #4043

CHI Drug Discovery Chemistry

April 9-11th, 2019
San Diego, CA

CPhI N. America

April 30-May 2nd, 2019
Chicago, IL
Booth #2254


Let's get in touch

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

Working hours

Monday- Thursday: 8:00-18:30 Hrs
(Phone until 17:30 Hrs)
Friday - 8:00-14:00

We are here

11011 Torreyana Rd. San Diego, CA 92121
Phone:+1 xx xxx xxxx
Fax:+1 xx xxxx xxxx

David Preston
David Preston


David Preston has had 38 years of healthcare experience with publicky Traded and Private companies in the fields of Phammaceuticals, Animal Health and Biotechnology as a Board Member. The last 30 years of his xperience has been in China, Taiwan and Hong Kong building successful igh growth businesses. David Has been Chaiman and CEO for Greater China for Sanofi and Boehringer – Ingelheim as well as the Janssen Corporation since 1991 in China. During this time he build high Growth ousinesses in China through diversified strategies in Innovative Pharmaceuticals. branded Generics. Biotechnology. and Animal Healthcare.

Key highlights in this period indluded building of the first Westem Multinational Biotechnoloqy C.M.O. facility as well as obtaining the first Test CM.OJ MAHI license. Establishment of a number of High tech Vaccine Plants, and R and D facilities in in the field of Animal Health. Signing and development of numerous JV’s as well as Wholly owned Subsidiaries. Mergers and Acquisitions across Phamaceutical’s. Animal Health. and Biotechnology industries

David’s achievement’s in the Healthcare industry and it Growth and development in China is widely recognized By the Chinese Govemnment and the City of Shanghai In 2013 he was awarded the Silver Magnolia ollowed in 2015 the Gold Magnolia award. This was then followed by being awarded in 2017 the Honorary Citizen of Shanghai by 40th People’s Municipal Congress of Shanghai. David Holds a Business Science Degree

This will close in 0 seconds

Filippo de Vecchi

Director, Advent Partner

Filippo de Vecchi joined Advent in February 2000. He started in the Advent São Paulo office, then moved to Milan in 2002, in 2012 set up the Advent office in Shanghai and in 2016 set up the Hong Kong office. Before joining Advent, he was a senior consultant with Value Partners, in São Paulo and Milan, focusing on strategy and organization in the automotive, energy, cable and media sectors. He began his career at Wasserstein Perella & Co., working as an analyst in the Mergers and Acquisitions department in London and New York. Filippo holds an undergraduate degree cum laude in Economics, with a major in Business Administration, from the LUISS University and an MBA from Columbia Business School, where he currently serves as a member of the Board of Overseers.

This will close in 0 seconds

Andrew Li
Andrew Li

Director, Advent Partner

Andrew Li joined Advent in 2012. He previously worked at Warburg Pincus, HSBC PE, Solera Capital and Credit Suisse where he focused on the retail and consumer, healthcare, industrial, and energy sectors. Andrew has worked in finance and private equity throughout the U.S. and China since 1999. Andrew holds a BA from Middlebury College and an MBA from Harvard Business School.    

This will close in 0 seconds

Michael Miltenberger
Michael Miltenberger

Director, Advent Partner

Michael Miltenberger  joined Advent in 2011 as an associate on the healthcare team. Following business school, he rejoined Advent’s Boston office, focusing on healthcare investments. Prior to Advent, Michael was a consultant at McKinsey & Company in their Washington DC office, serving a range of healthcare and private equity clients. Michael earned a BA, cum laude, from Harvard College and an MBA from Harvard Business School, graduating with High Distinction as a Baker Scholar and a Harvey Fellow.

This will close in 0 seconds

Masood Tayebi
Masood Tayebi, PhD

Director, Operating Partner

Dr. Masood Tayebi is the Founder of BioDuro. He currently serves as CEO of a nationwide real estate portfolio and is a Partner and Chief Executive Officer of the Bridgewest Group. Prior to BioDuro, Dr. Tayebi was Co-Founder and Chairman of Wireless Facilities, Inc. (NASDAQ: WFI), a global leader in telecommunications outsourcing.

  • Co-Founder of Wireless Facilities, Inc.

  • Co-Founder of BioAtla, LLC

  • Recipient of the Ernst and Young 2000 Entrepreneur of the Year award in San Diego

This will close in 0 seconds

Kewen Jin
Kewen Jin, PhD

Director, Operating Partner

This will close in 0 seconds

Amit patel
Amit Patel

Director, Operating Partner

Amit Patel has twenty years of healthcare industry experience with publicly-traded, private equity-backed, and start-up companies in the capacity of executive, board member, advisor, and investor.  He is currently Executive Chairman of Azurity Pharmaceuticals (a NovaQuest Capital Management portfolio company) and a board member at BioDuro (Advent International portfolio company), Tergus Pharma (Great Point Partners portfolio company) and Calyptus Pharma.  Recently, Amit was SVP & President of Dosage Form Solutions at Capsugel, a KKR portfolio company (purchased from Pfizer in 2011 and sold to Lonza in 2017).   

Prior to Capsugel, he worked at Dr. Reddy’s Laboratories, Inc. as EVP & Head of North America, and SVP & Head of Global Corporate Development & Strategic Planning. Earlier, Amit was VP of Corporate Development at CTIS, Inc., and Co-founder & CEO of MedOnTime, Inc. (acquired by CTIS).  He started his career as a strategy consultant with Marakon Associates. Amit holds an M.B.A. degree from Harvard Business School, a B.S. degree in Economics from the Wharton School of Business, University of Pennsylvania, and a B.A.S. degree in Systems Engineering from the Moore School of Engineering, University of Pennsylvania.

This will close in 0 seconds

Haijun Dong
Haijun Dong

Chief Executive Officer

Dr. Haijun Dong currently serves as global CEO of BioDuro-Sundia. He previously was CEO for over 5 years at PharmaBlock Sciences Inc., a public company listed in the Shenzhen Stock Exchange (300725.SZ). The positions he held prior to PharmaBlock includes, among others, Senior Scientist at Boehringer Ingelheim Pharmaceuticals in Ridgefield, Connecticut; Senior Principal Scientist at Roche in Nutley, New Jersey; Head of DMPK and Drug Safety at Roche China R&D Company in Shanghai; Chief Operating Officer of Eli Lilly China R&D Center in Shanghai.

Dr. Dong received his PhD in organic chemistry from the University of Washington in Seattle, Washington, and MBA from China Europe International Business School in Shanghai. 

This will close in 0 seconds

Teo Nee Chuan
Teo Nee Chuan

Chief Financial Officer

Teo Nee Chuan joined us in May 2021 as chief financial officer. Prior to joining us, he was chief financial officer of Huazhu Group from November 2015 to May 2021, and was the chief financial officer for Rnomac International Limited, from November 2011 to August 2015. Mr. Teo worked in DDB Greater China Group, was appointed as the chief financial officer in September 2009, and was additionally appointed as the director of operations in January 2011. He previously served in Focus Media Group and was appointed as the financial deputy director in June 2007. Prior to that, from September 1994 to May 2007, Mr. Teo worked at Ernst & Young and Ernst & Young Business Services Ltd. in various positions in Kuala Lumpur and Toronto, including as a senior manager in the Transaction Advisory Services. Mr. Teo has been an independent director of 111, Inc. (a company listed on the NASDAQ, ticker symbol: YI) since September 2018. Mr. Teo received his Bachelor of Science in Accounting and Financial Analysis degree from The University of Warwick in the United Kingdom in July 1994. He is a Chartered Certified Accountant in the United Kingdom, who has obtained his qualification in July 1998 from The Association of Chartered Certified Accountants, and is a Certified Public Accountant in the United States and Hong Kong, who has obtained his qualification from American Institute of Certified Public Accountants in May 2002 and Hong Kong Society of Accountants in October 2003, respectively.

This will close in 0 seconds

TJ Deng, PhD

President, Discovery

Dr TJ Deng joined BioDuro in the initial stages of the company and helped BioDuro grow to an industry leading discovery services organization. He established and managed several scientific departments, including DMPK, before transitioning to a leader of the business and operations functions. Prior to joining BioDuro, Dr. Deng spent six years at PPD, in positions with increasing responsibilities from scientist to scientific manager.




  • Developed the extractable/leachable capabilities at PPD
  • 18 years industry experience

This will close in 0 seconds

Kent Payne
Kent M. Payne, PhD

Chief Executive Officer

Kent is distinguished as a business operator and leader in areas of sales, commercial manufacturing and product development. He has extensive executive experience in M&A as well as successfully running, start up, growth and turn around businesses. This includes both Fortune 500 and Private Equity environments. He combines strong business leadership, successful P&L track record, and technical background to strategically lead and grow enterprise value across Biotechnology and Pharmaceutical market segments. He has successfully led the geographic expansion of businesses into Europe, Asia, and South America in addition to the United States.  He currently serves as CEO for BioDuro-Sundia, LLC (an Advent International company). He also currently serves as a board member for Goodwin Biotechnologies (a Signet Healthcare company). 

Prior Roles

  • President, Global CMC Solutions BioDuro-Sundia, a global
  • CEO Socorro Pharmaceuticals, LLC, a generic pharmaceutical
  • President Americas, Qualicaps Inc.(a Mitsubishi Chemical Holdings subsidiary)
  • Principal Consultant and Partner at CoreFactor LLC, providing executive strategic, licensing and operational advisory services to clients.
  • Vice President/General Manager Catalent Pharma Solutions, Inc. (a Blackstone Group company formed in 2007, formerly part of Cardinal Health)
  • Progressive leadership responsibility at: Novartis, Monsanto and G.D. Searle.  

Prior Brand Position

  • Board Advisor Vitruvias Therapeutics
  • Board Member Qualicaps, Inc. (a wholly owned subsidiary of
    Mitsubishi Chemical Holdings)
  • Board member Technophar, Inc. (a wholly owned subsidiary of
    Mitsubishi Chemical Holdings)
  • Board Advisor, Corporate Strategy Office, Life Science Institute
    Inc. (a wholly owned subsidiary of Mitsubishi Chemical Holdings)
  • Non-executive Chair and Board Member PDS Biotechnology·        (PDSB: NASDAQ)

This will close in 0 seconds

John Phillips
John Phillips

Vice President, Business Development (US & EU)

Coming soon…



  • Coming soon…

This will close in 0 seconds

Roy Xu
Roy Xu

Chief Strategy Officer

Roy has over 25 years of healthcare industry experience.  He started his career as an orthopedic surgeon.  Roy joined Eli Lilly as a sales rep in 1997.  Since then he has had various roles in market research, business intelligence, BU head, strategy, regional general management, business development etc., both at Eli Lilly and Boehringer Ingelheim (BI).  Roy also spent more than two years in Germany where he was BI’s Director of Corporate Business and Enabling Strategy.

Roy obtained a bachelor’s degree in Clinical Medicine at Zhejiang Traditional Chinese Medicine University, and an MBA from Zhejiang University.



  • 25 years of healthcare industry experience including Eli Lily and Boehringer Ingelheim. 
  • Former Director of Corporate Business & Enabling Strategy at oehringer Ingelheim in Germany.

This will close in 0 seconds

San Diego

San Diego - BioDuro-Sundia

Our San Diego site is our corporate headquarters. The facility is home to BioDuro-Sundia’s drug product development technologies and has 9 GMP clean rooms. Development and manufacturing operations are conducted for projects up to Phase III clinical trials.

Size: 44,000 sq. ft.
Featured capabilites: Tableting, Coating, Hot Melt Extrusion, Spray Dried Dispersion

11011 Torreyana Rd.
San Diego
CA 92121
United States

This will close in 0 seconds


BioDuro Beijing

Operating since 2006, our Beijing site is home to BioDuro-Sundia’s first wet chemistry operations. With 300 regular fume hoods and 18 scale-up chemistry hoods the Beijing facility houses most of BioDuro’s chemistry operations, while also hosting labs for biology and monoclonal antibody discovery.

Size: 100,000 sq. ft. 
Featured capabilities: Radioactivity Lab, Monoclonal Antibody Discovery, Medicinal Chemistry

No. 29 Life Science Park Road
Changping District Beijing,
P.R. China

This will close in 0 seconds


BioDuro- Shanghai Facility

Established in 2012, BioDuro-Sundia’s Shanghai facility has been growing with its departments. The cutting edge facility contains labs for ADME, bioanalysis, in vitro assays and translational research. The site includes a 18,000 sq. ft vivarium and 20,000 sq. ft of office space.

Size: 92,000 sq. ft.
Featured capabilities: Scale-up Chemistry, Discovery Biology, DMPK, In Vivo Pharmacology

No. 233 North Fu Te Road
Waigaoqiao Free Trade Zone
Shanghai, 200131
P.R. China

This will close in 0 seconds

Cathy Yen
Cathy Yen

Director, Operating Partner

Cathy joined the Board of Directors of BioDuro-Sundia in 2020, with the Advent-led acquisition of Sundia and creation of BioDuro-Sundia. Prior to that, she was Chairman of the Board at Sundia Meditech Group, where she was the key architect of Sundia’s strategic vision and growth. Under her leadership, Sundia solidified its position as one of the leading pre-clinical CROs in China.

Prior to Sundia, Cathy had a distinguished career as a seasoned venture capitalist, having led numerous investments in high-growth companies in Asia. Cathy served as a Partner of AsiaVest Partners, TCW/YFY Ltd., a global venture capital firm, for over a decade, Vice President at Global Financial Services, Vice President at Crimson Ventures/Chinatrust Bank and Senior Manager at Fortune Capital. She brings over 20 years of experience in corporate finance, accounting, strategic planning and private equity investments. 

This will close in 0 seconds